
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
Department of Urology, Dokkyo University School of Medicine, Tochigi 321-0293 [T. K., T. T., K. A.]; Departments of Urology [T. K., K. T.] and Pathology [H. A., Y. I.], Tokyo Metropolitan Tama Geriatric Hospital, Tokyo; and Department of Urology, Tokyo Medical and Dental University School of Medicine, Tokyo [H. O.], Japan
Purpose: The small GTP-binding protein Rho and its best-characterized downstream effector Rho-associated serine-threonine protein kinase, ROCK, participate in actin cytoskeleton organization, and are linked to pathogenesis and progression of several human tumors. We investigated the roles of Rho and ROCK in bladder cancer.
Experimental Design: Using Western blotting, we quantitated Rho and ROCK protein expression in paired tumor and nontumor surgical samples from 107 consecutive Japanese patients with bladder cancer.
Results: RhoA, RhoC, and ROCK were more abundant in tumors and metastatic lymph nodes than in nontumor bladder and uninvolved lymph nodes (P < 0.0001). Amounts of RhoA and RhoC protein, and ROCK protein expression correlated positively with one another (P < 0.0001). High RhoA, RhoC, and ROCK expression were related to poor tumor differentiation (P < 0.05, P < 0.01, and P < 0.01, respectively), muscle invasion (P < 0.001), and lymph node metastasis (P < 0.05). Kaplan-Meier plots linked high RhoA, RhoC, and ROCK protein expression to shortened disease-free and overall survival (P < 0.0001). By univariate analysis, high RhoA, RhoC, and ROCK protein expression predicted shortened disease-free and overall survival (P < 0.0001). By multivariate analysis, only RhoC was independently influenced in disease-free survival (P < 0.05), and RhoA and RhoC in overall survival (P < 0.001). In contrast, RhoB expression was inversely related to the grade and stage (P < 0.05), and its higher expression is associated with better overall survival (P < 0.05). In superficial tumors (Ta or T1; 63 patients), RhoA, RhoC, and ROCK were unrelated with recurrence-free survival. Overall survival in tumors invading muscle (T2 to T4; 44 patients) was significantly influenced by RhoA, RhoC, and ROCK in a Kaplan-Meier analysis (P < 0.0001, P < 0.0001, and P < 0.01, respectively). Whereas RhoA, RhoC, and ROCK independently predicted shortened overall survival in patients with invasive tumor by univariate analysis (P < 0.0001, P < 0.0001, and P < 0.01, respectively), only RhoC did so by multivariate analysis (P < 0.05).
Conclusion: Rho/ROCK pathway apparently involved in occurrence and progression of bladder cancer may be valuable prognostic markers.
This article has been cited by other articles:
![]() |
H. Li, C. Y. Ung, X. H. Ma, B. W. Li, B. C. Low, Z. W. Cao, and Y. Z. Chen Simulation of crosstalk between small GTPase RhoA and EGFR-ERK signaling pathway via MEKK1 Bioinformatics, February 1, 2009; 25(3): 358 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Zhao, L. Lu, N. Pokhriyal, H. Ma, L. Duan, S. Lin, N. Jafari, H. Band, and V. Band Overexpression of RhoA Induces Preneoplastic Transformation of Primary Mammary Epithelial Cells Cancer Res., January 15, 2009; 69(2): 483 - 491. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Laezza, S. Pisanti, A. M. Malfitano, and M. Bifulco The anandamide analog, Met-F-AEA, controls human breast cancer cell migration via the RHOA/RHO kinase signaling pathway Endocr. Relat. Cancer, December 1, 2008; 15(4): 965 - 974. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, F. Wu, F. Fang, Y. Tao, and L. Yang Inhibition of Invasion and Metastasis of Hepatocellular Carcinoma Cells via Targeting RhoC In vitro and In vivo Clin. Cancer Res., November 1, 2008; 14(21): 6804 - 6812. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Chen, E. Guerriero, K. Lathrop, and N. SundarRaj Rho/ROCK Signaling in Regulation of Corneal Epithelial Cell Cycle Progression Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 175 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Faried, L. S. Faried, N. Usman, H. Kato, and H. Kuwano Clinical and Prognostic Significance of RhoA and RhoC Gene Expression in Esophageal Squamous Cell Carcinoma Ann. Surg. Oncol., December 1, 2007; 14(12): 3593 - 3601. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Lu, K. L. Knutson, E. Gad, and M. L. Disis The Tumor Antigen Repertoire Identified in Tumor-Bearing Neu Transgenic Mice Predicts Human Tumor Antigens Cancer Res., October 1, 2006; 66(19): 9754 - 9761. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Croft and M. F. Olson The Rho GTPase Effector ROCK Regulates Cyclin A, Cyclin D1, and p27Kip1 Levels by Distinct Mechanisms Mol. Cell. Biol., June 15, 2006; 26(12): 4612 - 4627. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. H.-Y. Leung, Y.-P. Ching, J. W. P. Yam, C.-M. Wong, T.-O. Yau, D.-Y. Jin, and I. O.-L. Ng Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity PNAS, October 18, 2005; 102(42): 15207 - 15212. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-M. Wong, J. W.-P. Yam, Y.-P. Ching, T.-O. Yau, T. H.-Y. Leung, D.-Y. Jin, and I. O.-L. Ng Rho GTPase-Activating Protein Deleted in Liver Cancer Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma Cancer Res., October 1, 2005; 65(19): 8861 - 8868. [Abstract] [Full Text] [PDF] |
||||
![]() |
W-B Zhong, Y-C Liang, C-Y Wang, T-C Chang, and W-S Lee Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling Endocr. Relat. Cancer, September 1, 2005; 12(3): 615 - 629. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Titus, H. F. Frierson Jr., M. Conaway, K. Ching, T. Guise, J. Chirgwin, G. Hampton, and D. Theodorescu Endothelin Axis Is a Target of the Lung Metastasis Suppressor Gene RhoGDI2 Cancer Res., August 15, 2005; 65(16): 7320 - 7327. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ramirez de Molina, D. Gallego-Ortega, J. Sarmentero, M. Banez-Coronel, Y. Martin-Cantalejo, and J. C. Lacal Choline Kinase Is a Novel Oncogene that Potentiates RhoA-Induced Carcinogenesis Cancer Res., July 1, 2005; 65(13): 5647 - 5653. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Y. Lang, H. Chen, J. Zhou, Y.-X. Zhang, X.-W. Zhang, M.-H. Li, L.-P. Lin, J.-S. Zhang, M. P. Waalkes, and J. Ding Antimetastatic Effect of Salvicine on Human Breast Cancer MDA-MB-435 Orthotopic Xenograft Is Closely Related to Rho-Dependent Pathway Clin. Cancer Res., May 1, 2005; 11(9): 3455 - 3464. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhou and R. H. Kramer Integrin Engagement Differentially Modulates Epithelial Cell Motility by RhoA/ROCK and PAK1 J. Biol. Chem., March 18, 2005; 280(11): 10624 - 10635. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Croft, E. Sahai, G. Mavria, S. Li, J. Tsai, W. M. F. Lee, C. J. Marshall, and M. F. Olson Conditional ROCK Activation In vivo Induces Tumor Cell Dissemination and Angiogenesis Cancer Res., December 15, 2004; 64(24): 8994 - 9001. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Wang, S. Goswami, K. Lapidus, A. L. Wells, J. B. Wyckoff, E. Sahai, R. H. Singer, J. E. Segall, and J. S. Condeelis Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors Cancer Res., December 1, 2004; 64(23): 8585 - 8594. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. J. Simpson, A. S. Dugan, and A. M. Mercurio Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast Carcinoma Cancer Res., December 1, 2004; 64(23): 8694 - 8701. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Liu, F. Bi, Y. Pan, L. Sun, Y. Xue, Y. Shi, X. Yao, Y. Zheng, and D. Fan Reversal of the Malignant Phenotype of Gastric Cancer Cells by Inhibition of RhoA Expression and Activity Clin. Cancer Res., September 15, 2004; 10(18): 6239 - 6247. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. G. Strauss, A. Dimitrakopoulou-Strauss, D. Koczan, L. Bernd, U. Haberkorn, V. Ewerbeck, and H.-J. Thiesen 18F-FDG Kinetics and Gene Expression in Giant Cell Tumors J. Nucl. Med., September 1, 2004; 45(9): 1528 - 1535. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Vasiliev, T. Omelchenko, I. M. Gelfand, H. H. Feder, and E. M. Bonder From the Cover: Rho overexpression leads to mitosis-associated detachment of cells from epithelial sheets: A link to the mechanism of cancer dissemination PNAS, August 24, 2004; 101(34): 12526 - 12530. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kamai, T. Yamanishi, H. Shirataki, K. Takagi, H. Asami, Y. Ito, and K.-I. Yoshida Overexpression of RhoA, Rac1, and Cdc42 GTPases Is Associated with Progression in Testicular Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4799 - 4805. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. McHardy, R. Sinotte, A. Troussard, C. Sheldon, J. Church, D. E. Williams, R. J. Andersen, S. Dedhar, M. Roberge, and C. D. Roskelley The Tumor Invasion Inhibitor Dihydromotuporamine C Activates RHO, Remodels Stress Fibers and Focal Adhesions, and Stimulates Sodium-Proton Exchange Cancer Res., February 15, 2004; 64(4): 1468 - 1474. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Ikoma, T. Takahashi, S. Nagano, Y.-M. Li, Y. Ohno, K. Ando, T. Fujiwara, H. Fujiwara, and K.-i. Kosai A Definitive Role of RhoC in Metastasis of Orthotopic Lung Cancer in Mice Clin. Cancer Res., February 1, 2004; 10(3): 1192 - 1200. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |